A new analysis finds that prior authorization for anti-VEGF therapies increases societal costs despite minimal insurer savings, burdening patients, workplaces, and providers.

Operator: Hello, and thank you for standing by. My name is Bella, and I will be your conference operator today.

President Donald Trump gave Senate Republicans permission to begin their August recess Saturday night, shortly before ...

Operator: Good afternoon, and thank you for standing by. Welcome to Forrester’s Second Quarter 2025 Conference Call.